Compare
Neuraxis, Inc vs Hongchang International Co., Ltd vs Nuwellis, Inc. vs Escalon Medical Corp
| Latest fiscal year | Neuraxis, Inc NRXS | Hongchang International Co., Ltd HCILLast annual report: year ended 2024-12-31 | Nuwellis, Inc. NUWE | Escalon Medical Corp ESMC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2024-12-31 | 2025-12-31 | 2025-06-30 |
| Revenue | $3.57M | $2.87M | $8.27M | $12.05M |
| Revenue growth (YoY) | +32.9% | +7.1% | -5.4% | +0.5% |
| Gross margin | 84.2% | 6.3% | 62.0% | 45.7% (computed) |
| Operating margin | -219.4% | -13.4% | -134.3% | 1.1% |
| Net margin | -218.5% | -16.5% | -211.9% | 0.9% |
| Net income | -$7.80M | -$472.4K | -$17.52M | $105.5K |
| EPS (Diluted) | -$0.95 | $0.00 | -$25.39 | $0.00 |
| Operating cash flow | -$6.43M | -$7.34M | -$10.81M | $380.7K |
| Free cash flow | -$6.46M | -$11.36M | -$10.90M | $376.8K |
| Cash & equivalents | $4.97M | n/a | $1.08M | $545.8K |
| Total assets | $6.40M | $57.45M | $6.12M | $4.99M |
| Total liabilities | $3.00M | $18.68M | $3.49M | $3.08M |
| Shareholders' equity | $3.40M | $38.77M | $2.62M | $1.92M |
| Return on year-end equity | -229.5% | -1.2% | -667.7% | 5.5% |
| Shares outstanding | 10.65M | 518.83M | 1.69M | 7.42M |
Revenue, most recent five fiscal years
| Fiscal year | Neuraxis, Inc | Hongchang International Co., Ltd | Nuwellis, Inc. | Escalon Medical Corp |
|---|---|---|---|---|
| Latest | $3.57M Ended 2025-12-31 | $2.87M Ended 2024-12-31 | $8.27M Ended 2025-12-31 | $12.05M Ended 2025-06-30 |
| 1 year earlier | $2.69M Ended 2024-12-31 | $2.68M Ended 2023-12-31 | $8.74M Ended 2024-12-31 | $11.98M Ended 2024-06-30 |
| 2 years earlier | $2.46M Ended 2023-12-31 | $79.0K Ended 2022-12-31 | $8.86M Ended 2023-12-31 | $12.18M Ended 2023-06-30 |
| 3 years earlier | $2.68M Ended 2022-12-31 | $96.5K Ended 2021-12-31 | $8.54M Ended 2022-12-31 | $10.70M Ended 2022-06-30 |
| 4 years earlier | n/a | $222.7K Ended 2020-12-31 | $7.92M Ended 2021-12-31 | $10.47M Ended 2021-06-30 |